Author Correction: IDH1-mutant vaccine in newly diagnosed astrocytoma: final analysis of the multicenter, single-arm, open-label, first-in-human phase 1 NOA16 trial

Nature Cancer 2026 Open access

Read full text
Authors: Lukas Bunse, Katharina A.M. Lindner, Antje Wick, Angelika Freitag, Lisa-Marie Lanz, Dominic Edelmann, Abigail Suwala, Michael O. Breckwoldt, Inga Harting, Felix Sahm, Richard F. Schlenk, Anita Schmitt
+15 more Oliver Schnell, J. Hense, Martin Misch, Dietmar Krex, Monika Denk, Juliane S. Walz, Joachim P. Steinbach, Andreas von Deimling, Michael W. Schmitt, Theresa Bunse, Ghazaleh Tabatabai, Martin Bendszus, Isabel Poschke, Wolfgang Wick, Michael Platten
DOI: 10.1038/s43018-026-01227-x
Cited by: 2

Abstract

In the version of the article initially published, in the Abstract, the sentence “The 8-year progression-free and overall survival (OS) rates were 0.42 months (confidence interval (CI): 0.24–0.59) and 0.66 months (CI: 0.46–0.79), respectively” should have read “The 8-year progression-free and overall survival (OS) rates were 0.42 (confidence interval (CI): 0.24–0.59) and 0.66 (CI: 0.46–0.79), respectively”. This correction has been made to the HTML and PDF versions of the article.

Publication details

Journal / source
Nature Cancer
Publisher
Springer Science and Business Media LLC
Volume
7
Issue
8
Pages
1322–1322
Publication date
3 August 2026
Language
EN